Compare · PRPO vs RVTY
PRPO vs RVTY
Side-by-side comparison of Precipio Inc. (PRPO) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRPO and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $12.33B, about 291.1x PRPO ($42.4M).
- Over the past year, PRPO is up 63.4% and RVTY is up 14.3% - PRPO leads by 49.1 points.
- Both names hit the wire about 3 times in the past 4 weeks.
- RVTY has more recent analyst coverage (20 ratings vs 0 for PRPO).
- Company
- Precipio Inc.
- Revvity Inc.
- Price
- $23.48+1.27%
- $109.86-0.52%
- Market cap
- $42.4M
- $12.33B
- 1M return
- +3.96%
- +10.95%
- 1Y return
- +63.36%
- +14.28%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 3
- Recent ratings
- 0
- 20
Precipio Inc.
Precipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The company also operates a cancer diagnostic laboratory located in New Haven, Connecticut. It sells ICE-COLD-PCR technology kits to bio-pharma customers, clinical research, HemeScreen, and COVID-19 antibody tests. The company serves oncologists, hospitals, reference laboratories, physician-office labs, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania. The company is based in New Haven, Connecticut.
Latest PRPO
- Director Valauri Christina Rizopoulos was granted 108 shares, increasing direct ownership by 2% to 5,628 units (SEC Form 4)
- Director Cossman Jeffrey was granted 416 shares, increasing direct ownership by 3% to 16,549 units (SEC Form 4)
- Director Cohen David Seth was granted 520 shares, increasing direct ownership by 0.95% to 55,199 units (SEC Form 4)
- Precipio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
- Precipio to Present at the Planet MicroCap Las Vegas
- Director Sandberg Richard A sold $22,517 worth of shares (900 units at $25.02) (SEC Form 4)
- Director Sandberg Richard A sold $77,784 worth of shares (3,134 units at $24.82), decreasing direct ownership by 20% to 8,142 units (SEC Form 4)
- Precipio Announces Q1 2026 Financial Results
- SEC Form 10-Q filed by Precipio Inc.
Latest RVTY
- Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
- Revvity to Hold Earnings Call on Tuesday, August 4, 2026
- Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration
- Bernstein resumed coverage on Revvity with a new price target
- SEC Form 11-K filed by Revvity Inc.
- Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D
- Vice President and CAO Gonzales Anita covered exercise/tax liability with 33 shares, decreasing direct ownership by 0.45% to 7,286 units (SEC Form 4) to cover taxes
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.